Overall Score

Revenue Model

TVTX remains a commercial-stage biotech with revenue generation reflected in TTM revenue per share of 6.33 and a high gross margin of 94.4%.

The business is still loss-making on a TTM basis, with net profit margin at -7.4% and operating margin at -6.8%, indicating the revenue base has not yet translated into durable profitability.

Unit Economics

Gross margin remains very strong at 94.4%, supporting attractive product-level economics.

However, TTM operating cash flow margin is only 15.7% and free cash flow margin is 55.6% of operating cash flow, while price-to-free-cash-flow remains elevated at 111.0x, suggesting economics are still not yet compelling at the enterprise level.

Scalability

The company shows strong asset efficiency with fixed asset turnover of 49.3x and asset turnover of 0.74x, which supports scalability if revenue continues to expand.

That said, high SG&A at 61.6% of revenue and R&D at 38.4% of revenue indicate the operating model still requires heavy investment to scale.

Customer Retention

No direct retention metrics are provided, so customer stickiness must be inferred from the recurring commercial revenue base rather than measured explicitly.

The current business profile does not yet provide enough evidence to rate retention as a clear strength or weakness.

Pricing Power

The 94.4% gross margin suggests meaningful pricing power or a favorable product mix.

However, the very high price-to-sales ratio of 9.7x and negative earnings imply the market is still pricing in future growth rather than proven monetization strength.

Capital Intensity

Capital intensity appears moderate, with capex at 7.0% of revenue and capex-to-operating-cash-flow at 44.4%.

Still, the balance sheet remains highly leveraged on a debt-to-equity basis (25.2x), which limits financial flexibility despite a current ratio of 4.0x.

Operating Leverage

The company has not yet demonstrated strong operating leverage, as EBIT margin is -9.7% and operating profit margin is -6.8%.

High fixed cost absorption is still a work in progress, with SG&A and R&D consuming a large share of revenue.

Competitive Moat

A 94.4% gross margin and strong fixed-asset turnover suggest the business may have some product or process advantages.

But the absence of positive TTM profitability and the lack of direct retention or market-share data keep the moat assessment at a moderate level.